News

Tarceva is currently approved as a monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) patients who have failed prior chemotherapy, and in combination with the

Orphan drug status, given to drugs intended to treat diseases afflicting less than 200,000 people in the US, will entitle Xechem to various incentives, including the waiving of

This trial is being sponsored by the US National Cancer Institute (NCI) under an agreement with CuraGen and will be conducted at multiple sites in the US. Up

As patients with advanced cancer may often have limited function of the liver and/or kidneys, it is important to understand how these impairments affect how a drug is

The study found that patients receiving any dose of Hi-8 MEL who developed a CD8+ response specific to melan-A (one of seven melanoma-specific epitopes used in the Hi-8

In the phase III, open-label study, 430 patients with metastatic colorectal cancer (mCRC) were randomized to receive first-line treatment with one of three Campto-based regimens: Folfiri, mIFL or

The approval covers the reintroduction of Tysabri (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the

This agreement further strengthens the collaboration between the companies that began with the development and commercialization agreement for PTH1-34 nasal spray that was announced in February. Under terms

The offer will be GBP10.50 ($19.53) in cash for each NeuTec Share, which values the existing issued share capital of NeuTec at approximately GBP305.1 million ($568 million). The